68-Gallium DOTATATE for neuroendocrine tumors

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 29 Aug 2019: Trial registered, NCT04074135
  2. 2 Jun 2020: Trial started, NCT04074135

The trials

NCT04074135: Natural History and Management of Von Hippel-Lindau (VHL) Associated Pancreatic Neuroendocrine Tumors

State
Under way
Phase
Phase 2
People
740 planned
Started
2 Jun 2020
Primary completion
30 Jan 2036
Arms
1/ Arm 1
Results
None posted
  1. 29 Aug 2019: Trial registered
  2. 2 Jun 2020: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

About the treatment

Kind of treatment: Drug.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.